These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Preface: insights into an unsolved problem in drug delivery. Bergstrom DE; Wei A J Control Release; 2012 Dec; 164(2):107. PubMed ID: 23046619 [No Abstract] [Full Text] [Related]
7. Preface: Nanoformulations for combination or cascade anticancer therapy. Zhang Q; Huang L Adv Drug Deliv Rev; 2017 Jun; 115():1-2. PubMed ID: 28887913 [No Abstract] [Full Text] [Related]
8. Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy. Moosavian SA; Bianconi V; Pirro M; Sahebkar A Semin Cancer Biol; 2021 Feb; 69():337-348. PubMed ID: 31585213 [TBL] [Abstract][Full Text] [Related]
9. Application of Carbon Nanoparticles in Oncology and Regenerative Medicine. Lisik K; Krokosz A Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361101 [TBL] [Abstract][Full Text] [Related]
10. Functional recruitment for drug delivery through protein-based nanotechnologies. Vazquez E; Mangues R; Villaverde A Nanomedicine (Lond); 2016 Jun; 11(11):1333-6. PubMed ID: 27221076 [No Abstract] [Full Text] [Related]
11. Recent advances in "smart" delivery systems for extended drug release in cancer therapy. Kalaydina RV; Bajwa K; Qorri B; Decarlo A; Szewczuk MR Int J Nanomedicine; 2018; 13():4727-4745. PubMed ID: 30154657 [TBL] [Abstract][Full Text] [Related]
12. Nanoparticle approaches to combating drug resistance. Moon JH; Moxley JW; Zhang P; Cui H Future Med Chem; 2015 Aug; 7(12):1503-10. PubMed ID: 26334205 [TBL] [Abstract][Full Text] [Related]
14. Membrane-core nanoparticles for cancer nanomedicine. Guo J; Huang L Adv Drug Deliv Rev; 2020; 156():23-39. PubMed ID: 32450105 [TBL] [Abstract][Full Text] [Related]
15. Programmable nanomedicine: synergistic and sequential drug delivery systems. Pacardo DB; Ligler FS; Gu Z Nanoscale; 2015 Feb; 7(8):3381-91. PubMed ID: 25631684 [TBL] [Abstract][Full Text] [Related]
16. Emerging potential of stimulus-responsive nanosized anticancer drug delivery systems for systemic applications. Ruttala HB; Ramasamy T; Madeshwaran T; Hiep TT; Kandasamy U; Oh KT; Choi HG; Yong CS; Kim JO Arch Pharm Res; 2018 Feb; 41(2):111-129. PubMed ID: 29214601 [TBL] [Abstract][Full Text] [Related]
17. Nanomedicine strategies for sustained, controlled and targeted treatment of cancer stem cells. Gao J; Li W; Guo Y; Feng SS Nanomedicine (Lond); 2016 Dec; 11(24):3261-3282. PubMed ID: 27854161 [TBL] [Abstract][Full Text] [Related]
18. Nanomedicine: the promise and challenges in cancer chemotherapy. Naguib YW; Cui Z Adv Exp Med Biol; 2014; 811():207-33. PubMed ID: 24683034 [No Abstract] [Full Text] [Related]
19. Surface-active liposomes for targeted cancer therapy. Sofou S Nanomedicine (Lond); 2007 Oct; 2(5):711-24. PubMed ID: 17976032 [TBL] [Abstract][Full Text] [Related]
20. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics. Zhang W; Liu M; Liu A; Zhai G Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]